One year in review 2020: novelties in the treatment of rheumatoid arthritis

Ettore Silvagni, Alessandro Giollo, Garifallia Sakellariou, Nicola Ughi, Maria Ester D'Amico, Carlo Alberto Scirè, Tom W.J. Huizinga

Research output: Contribution to journalReview articlepeer-review

Abstract

Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR recommendations help in refining the relevant place of different disease-modifying anti-rheumatic drugs (DMARDs) in treatment schedules. At present, new drugs are in phase of development, mainly Janus Kinase inhibitors (JAKis), however, specific treatment strategies seem to count more than individual DMARDs in terms of treatment responses, given the substantial lack of head-to-head comparisons between specific biological (b) and targeted synthetic (ts)DMARDs, and with the general perception of a similar efficacy profile across drugs. In this setting, when reliable biomarkers able to predict treatment responses are lacking, treatment decisions are mainly driven by specific clinical or individual factors, given the recognised role of comorbidities, treatment-specific side effects, patients’ preferences, and costs on drug choice. In this narrative review, the authors give their specific point of view on the management of RA, based on a critical revision of the literature published in 2019, focusing on relevant novelties and future research directions.

Original languageEnglish
Pages (from-to)181-194
Number of pages14
JournalClinical and Experimental Rheumatology
Volume38
Issue number2
Publication statusPublished - Mar 1 2020

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'One year in review 2020: novelties in the treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this